Skip Navigation


NDT Plus Advance Access originally published online on January 14, 2008
NDT Plus 2008 1(2):85-88; doi:10.1093/ndtplus/sfm048
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
1/2/85    most recent
sfm048v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Deegens, J. K. J.
Right arrow Articles by Wetzels, J. F. M.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Rituximab for plasma exchange-dependent recurrent focal segmental glomerulosclerosis after renal transplantation

Jeroen K. J. Deegens and Jack F. M. Wetzels

Department of Nephrology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands

Correspondence: Jeroen K. J. Deegens, Department of Nephrology 464, Radboud University Nijmegen Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands. Tel: +31-243614761; Fax: +31-243540022; E-mail: j.deegens@nier.umcn.nl

Key Words: focal segmental glomerulosclerosis • recurrence • renal transplantation • rituximab

Received for publication December 10, 2007. Accepted for publication December 18, 2007.

The first 10% of the full text of this article appears below.


   Introduction
 
Focal segmental glomerulosclerosis (FSGS) can recur after renal transplantation and is associated with a reduced graft survival. In the case of recurrent FSGS, treatment with plasma exchange (PE) results in a remission of proteinuria in up to 85% of patients, especially if started shortly after the onset of recurrence [1,2]. However, many patients require repeated courses of PE because of frequent relapses [1,3]. Recently, a 7-year-old boy with recurrent FSGS after renal transplantation responded to rituximab, a monoclonal anti-CD20 antibody, that was administered for a transplantation-related lymphoma [4]. Following this report, several other cases with recurrent FSGS after renal transplantation were published, showing varying degrees of success after treatment with rituximab [5]. We describe . . . [Full Text of this Article]


   Case
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?